Cardiac Resynchronization Therapy—Emerging Therapeutic Approaches

被引:5
作者
Chatterjee N.A. [1 ,2 ]
Heist E.K. [1 ,2 ]
机构
[1] Cardiology Division and Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, 02114, MA
[2] Cardiology Division of the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, MA
关键词
Cardiac resynchronization therapy; Heart failure; His bundle pacing; Leadless pacing;
D O I
10.1007/s11936-018-0614-2
中图分类号
学科分类号
摘要
Cardiac resynchronization therapy (CRT) is an important therapeutic tool in the management of patients with heart failure and electrical dyssynchrony. In appropriately selected patients, landmark randomized controlled trials have demonstrated morbidity and mortality benefit beyond standard goal-directed medical therapy. Current guidelines emphasize the greatest clinical efficacy of CRT in patients with symptomatic heart failure, left bundle branch block, and wide QRS duration (CloseSPigtSPi 150 ms). Other relevant considerations include the presence of atrial fibrillation, the presence of AV block, the etiology of cardiomyopathy, the presence of masked left-sided conduction delay, and the impact of comorbidities that might predict poor clinical response. At the time of CRT implantation, key considerations include targeting of the left ventricular (LV) lead to sites of greatest electrical and/or mechanical delay, the use of quadripolar versus bipolar LV pacing leads, evaluation of multiple pacing vectors to maximize electrical resynchronization, and in select instances pre-procedure imaging of the coronary venous anatomy to help guide decision-making at the time implant. Post-implant care includes the selective use of atrio-ventricular and inter-ventricular optimization algorithms, mitigation of right ventricular pacing, recognition, and treatment of suboptimal biventricular pacing, as well as management by a multi-disciplinary team of cardiovascular specialists. Emerging therapeutic strategies for patients eligible for CRT include the use of endocardial LV pacing, novel LV pacing options including multi-point pacing, His bundle pacing, and the integration of remote monitoring platforms that may identify patients at risk for clinical worsening. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 81 条
[31]  
Upadhyay G.A., Choudhry N.K., Auricchio A., Ruskin J., Singh J.P., Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies, J Am Coll Cardiol, 52, 15, pp. 1239-1246, (2008)
[32]  
Wilton S.B., Leung A.A., Ghali W.A., Faris P., Exner D.V., Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis, Heart Rhythm: Off J Heart Rhythm Soc, 8, 7, pp. 1088-1094, (2011)
[33]  
Healey J.S., Hohnloser S.H., Exner D.V., Birnie D.H., Parkash R., Connolly S.J., Krahn A.D., Simpson C.S., Thibault B., Basta M., Philippon F., Dorian P., Nair G.M., Sivakumaran S., Yetisir E., Wells G.A., Tang A.S.L., Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the resynchronization for ambulatory heart failure trial (RAFT), Circ Heart Fail, 5, 5, pp. 566-570, (2012)
[34]  
Yin J., Hu H., Wang Y., Xue M., Li X., Cheng W., Li X., Yan S., Effects of atrioventricular nodal ablation on permanent atrial fibrillation patients with cardiac resynchronization therapy: a systematic review and meta-analysis, Clin Cardiol, 37, 11, pp. 707-715, (2014)
[35]  
Barsheshet A., Goldenberg I., Moss A.J., Eldar M., Huang D.T., McNitt S., Klein H.U., Hall W.J., Brown M.W., Goldberger J.J., Goldstein R.E., Schuger C., Zareba W., Daubert J.P., Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT, Eur Heart J, 32, 13, pp. 1622-1630, (2011)
[36]  
Chatterjee N.A., Roka A., Lubitz S.A., Gold M.R., Daubert C., Linde C., Steffel J., Singh J.P., Mela T., Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review, Eur Heart J, 36, 41, pp. 2780-2789, (2015)
[37]  
Kober L., Thune J.J., Nielsen J.C., Haarbo J., Videbaek L., Korup E., Et al., Defibrillator implantation in patients with nonischemic systolic heart failure, N Engl J Med, 375, 13, pp. 1221-1230, (2016)
[38]  
Barra S., Boveda S., Providencia R., Sadoul N., Duehmke R., Reitan C., Et al., Adding defibrillation therapy to cardiac resynchronization on the basis of the myocardial substrate, J Am Coll Cardiol, 69, 13, pp. 1669-1678, (2017)
[39]  
Fung J.W., Szeto C.C., Chan J.Y., Zhang Q., Chan H.C., Yip G.W., Et al., Prognostic value of renal function in patients with cardiac resynchronization therapy, Int J Cardiol, 122, 1, pp. 10-16, (2007)
[40]  
Garg N., Thomas G., Jackson G., Rickard J., Nally J.V., Tang W.H., Et al., Cardiac resynchronization therapy in CKD: a systematic review, Clin J Am Soc Nephrol: CJASN, 8, 8, pp. 1293-1303, (2013)